Cerus Corporation (NASDAQ:CERS) announced that Unyts has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma. Unyts provides blood components to eight counties inWestern New York, supplying approximately 5,000 platelet and 11,000 plasma units per year.

“Since adding community blood banking services in 2007, Unyts has continuously strived to find ways to utilize the latest innovative technologies to improve safety and availability,” saidMark Simon, Unyts President and CEO. “The INTERCEPT blood system will provide a proactive approach to addressing the safety of our platelet and plasma recipients by protecting these patients from transfusion transmitted bacteria and emerging pathogens.”

“We are pleased to add Unyts to our growing list of customers in the US,” commented William “Obi” Greenman, Cerus’ president and chief executive officer. “Unyts can now offer its hospitals state of the art platelet and plasma components processed with the INTERCEPT system.” (Original Source)

Shares of Cerus closed yesterday at $5.75. CERS has a 1-year high of $7.03 and a 1-year low of $3.48. The stock’s 50-day moving average is $5.32 and its 200-day moving average is $4.96.

On the ratings front, Cerus has been the subject of a number of recent research reports. In a report issued on June 29, MLV & Co. analyst Thomas Yip reiterated a Buy rating on CERS, with a price target of $10, which implies an upside of 73.9% from current levels. Separately, on May 27, Cantor Fitzgerald’s Caroline Corner reiterated a Buy rating on the stock and has a price target of $7.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Thomas Yip and Caroline Corner have a total average return of 6.0% and -8.9% respectively. Yip has a success rate of 50.0% and is ranked #1623 out of 3711 analysts, while Corner has a success rate of 38.1% and is ranked #3421.

Cerus Corp is a biomedical products company. It is engaged indeveloping andcommercializing the INTERCEPT Blood System to enhance blood safety.